drugset / Trial / NCT00191854
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
RandomizedParallel-groupOpen-labelTreatment
Summary
The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined. The primary objective of this study is to compare the response rates of the gemcitabine-paclitaxel, gemcitabine-carboplatin, and gemcitabine-cisplatin combinations when administered on a biweekly schedule in metastatic breast cancer.
Timeline
- Start
- 2005-03
- Primary completion
- 2008-08
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2.5 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 2500 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 150 mg/m2 | Intravenous |